Changes in Hong Kong stocks | Hebo Pharmaceutical-B (02142) rose more than 3% to fight pancreatic cancer jointly declared with Changhai Hospital and was approved as a major national science and technology innovation project

The Zhitong Finance App learned that Hebo Pharmaceutical-B (02142) rose more than 3%. As of press release, it had risen 3.34% to HK$12.67, with a turnover of HK$3.0805 million.

According to the news, on January 7, according to Hebo Pharmaceutical's official WeChat account, recently, the results of the National Science and Technology Innovation 2030 “Cancer, Cardiovascular, Respiratory and Metabolic Disease Prevention Research” major project in 2025 were officially announced. The “Pancreatic Cancer Pathogenesis and New Paradigm Research on Accurate Clinical Diagnosis and Treatment” project led by Shanghai Changhai Hospital and participated in the joint declaration with Platinum Pharmaceuticals was successfully approved.

According to reports, Heplatinum Pharmaceuticals has always focused on the research and development of innovative antibody therapeutics in the field of cancer and immune diseases. Using Harbour Mice®, an all-human genetically-modified mouse platform, the company has built more than 20 product pipelines covering dual antibodies, multiple antibodies, antibody conjugate drugs (ADC), etc., and has established deep cooperation with many world-renowned pharmaceutical companies such as AstraZeneca, Pfizer, Bristol-Myers Squibb, Otsuka Pharmaceuticals, AbbVie, Moderna, etc., and its technical strength has been widely recognized by partners.

In addition, the company's innovative therapies targeting targets such as CLDN18.2 and LIFR have also entered the clinical or reporting stage, injecting diversified momentum into the pancreatic cancer treatment matrix.